CRISPR/CAS-related methods and compositions for treating herpes simplex virus
AssigneeEditas Medicine, Inc.
InventorsAri E. Friedland, Penrose O'Donnell, David A. Bumcrot
Life of this patent
Estimating the term…
Abstract
CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
Claims21
A vector comprising a polynucleotide encoding a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a Herpes simplex virus (HSV) viral gene selected from the group consisting of a RS1 gene, a RL2 gene, and a LAT gene, wherein the targeting domain comprises a nucleotide sequence that is identical to, or differs by no more than 3 nucleotides from, a nucleotide sequence selected from the nucleotide sequences set forth in SEQ ID NOS:
- 208 to 58749.
Dependencies are inferred from the claim text.